Angiogenesis as Risk Factor for Plaque Vulnerability

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|15|10|1095-1106

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.10, 2009-04, pp. : 1095-1106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Animal Models to Study Plaque Vulnerability

By  

Current Pharmaceutical Design, Vol. 13, Iss. 10, 2007-04 ,pp. : 1013-1020

Bentham Science Publishers

Access to resources Recommend Favorite

Update on the Evidence of Statin Treatment to Reduce Plaque Vulnerability

By  

Drug Metabolism Letters, Vol. 6, Iss. 3, 2012-09 ,pp. : 151-156

Bentham Science Publishers

Access to resources Recommend Favorite

Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability

By  

Current Drug Targets, Vol. 16, Iss. 4, 2015-04 ,pp. : 321-333

Bentham Science Publishers

Access to resources Recommend Favorite

Basic fibroblast growth factor and the complexity of tumour angiogenesis

By Rak J.   Kerbel R.S.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 797-801

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)

By  

Current Gene Therapy, Vol. 4, Iss. 2, 2004-06 ,pp. : 199-206

Bentham Science Publishers

Access to resources Recommend Favorite